The best window for recovery is in the first six months after getting COVID-19, with better odds for people whose initial illness was less severe, as well as those who are vaccinated, researchers in the United Kingdom and the United States found
New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.
... For high-risk individuals, this could provide critical information to inform immediate treatment options, including quickly taking medications like Paxlovid within one week of symptoms to mitigate a severe response.
A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.
